Resistance of ERBB2 KD mutants to tesevatinib

Stable Identifier
R-HSA-9665245
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Resistance of ERBB2 KD mutants to tesevatinib
Click the image above or here to open this pathway in the Pathway Browser
This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor tesevatinib (Trowe et al. 2018).
Literature References
PubMed ID Title Journal Year
18413839 EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation

Trowe, T, Fong, R, Woolfrey, JR, Lamb, P, Yang, JP, Gerritsen, ME, Cutler, RE, Miller, N, Vysotskaia, V, Funke, R, Kim, YD, Gendreau, SB, Heuer, TS, Boukouvala, S, Matthews, DJ, Calkins, K

Clin. Cancer Res. 2008
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
BioModels Database
Authored
Orlic-Milacic, M  (2019-10-30)
Reviewed
Kancha, RK  (2019-09-16)
Created
Orlic-Milacic, M  (2019-10-30)
Cite Us!